And now we wait: FDA CBD powwow one for the books
The dust still has not settled from the May 31, full-day FDA hearing on CBD. It’s not obvious whether the meeting of the minds made things clearer or just further muddied the waters.
At the hearing, 120-plus interested professionals spoke in front of 12 FDA bureaucrats in Silver Spring, Md. The majority of witnesses believe the FDA has existing rulemaking tools and should expedite designating CBD as a "dietary supplement." Some want expedited FDA action, or temporary emergency rules, citing the consumer "explosion" of interest.
Everyone wants to see upgraded truth-in-labeling protocols, especially in terms of dosing information. Others would like a national testing regime for safety (and efficacy) helping to push out CBD "online fakers" and quick-buck "CBD private labelers."